News >

Cemiplimab Under Investigation in Cervical Cancer

Angelica Welch
Published: Wednesday, Oct 03, 2018

Krishnansu S. Tewari, MD

Krishnansu S. Tewari, MD
The treatment options for patients with cervical cancer has been historically limited, but a new study of the anti–PD-1 agent cemiplimab (Libtayo) may prove the benefit of immunotherapy in this disease.

Cemiplimab is currently approved by the FDA for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x